Stay Ahead of the Curve on CDK4/6 Inhibitor Toxicities

Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle and dietary techniques to improve tolerance of this treatment.   Diana Van Ostran, PharmD, BCOP  Clinical Pharmacy Specialist – Breast Clinic Miami Cancer Institute Baptist Health South Florida  Miami, FL   "Clinical pharmacists play a vital role in managing the patient's treatment. Because, as we know, if you're having excessive side effects, patients are going to be less likely to take their medications."   Resources: ACCC Adverse Event Management for CDK Inhibitors in HR+ Breast Cancer ACCC CDK Inhibitors Management Miami Cancer Institute ACCC Spotlight on Miami Cancer Institute: The Role of a Breast Cancer Clinical Pharmacy Specialist for CDK4/6 Inhibitor Management